Loading people...
Krishna Yeshwant is a General Partner at GV (formerly Google Ventures), specializing in healthcare and life sciences investments. He is known for his unique background as both a physician and a computer scientist.
Krishna Yeshwant primarily invests in healthcare and life sciences companies. His focus areas include biotechnology, digital health, medical devices, diagnostics, and the application of artificial intelligence in healthcare.
Krishna Yeshwant works as a General Partner at GV, which is the venture capital arm of Alphabet Inc. (formerly Google Ventures).
Krishna Yeshwant is a Managing Partner at GV (Google Ventures) co-leading the life sciences group, and is based in Boston, Massachusetts. He holds an MD from Harvard Medical School, an MBA from Harvard Business School, and a BS in Computer Science from Stanford University, having completed his internal medicine residency at Brigham and Women’s Hospital. Prior to his venture capital career, Yeshwant helped launch an electronic data interchange startup that was acquired by Hewlett-Packard and a network security firm purchased by Symantec. At GV, he has directed investments into healthcare entities including Flatiron Health, Foundation Medicine, and One Medical, while also establishing an incubation program that launched ROME Therapeutics and Verve Therapeutics. His current focus combines his dual expertise as a physician and programmer to fund early-stage companies across therapeutics, health IT, and care delivery.
Krishna Yeshwant stands as a distinguished General Partner at GV, formerly Google Ventures, where he plays a pivotal role in shaping the future of healthcare and life sciences. His investment philosophy is deeply rooted in identifying and supporting companies that are poised to revolutionize patient outcomes and advance scientific understanding.
At GV, Krishna Yeshwant's primary focus areas include biotechnology, digital health, medical devices, diagnostics, and the application of artificial intelligence within the healthcare ecosystem. He seeks out innovative startups that are developing groundbreaking therapies, improving healthcare delivery, or leveraging data and technology to solve complex medical challenges. His portfolio reflects a commitment to ventures that promise significant impact and long-term value.
Yeshwant's career background is uniquely suited to his investment role. Before joining GV in 2011, he completed his medical training at Brigham and Women's Hospital and Harvard Medical School, practicing as a physician. This clinical experience provides him with an invaluable first-hand understanding of the healthcare system's needs and opportunities. Prior to his medical career, he studied computer science at MIT and worked in software development, equipping him with a strong technical foundation. This rare combination of medical expertise and technological acumen allows him to critically evaluate complex scientific and technical propositions, making him a highly effective investor in the life sciences space.
Throughout his tenure at GV, Krishna Yeshwant has been instrumental in backing numerous successful and impactful companies. His notable investments include pioneering firms such as Flatiron Health (acquired by Roche), One Medical (acquired by Amazon), Foundation Medicine (acquired by Roche), GRAIL (acquired by Illumina), and Verily (an Alphabet company). He has also supported innovative companies like Relay Therapeutics, Monte Rosa Therapeutics, Freenome, and Insitro, among others. These investments underscore his ability to identify companies with strong scientific foundations and significant market potential, ultimately contributing to advancements in global health.
Krishna Yeshwant continues to be a leading voice and investor in the healthcare technology and biotechnology sectors, driving GV's mission to invest in the world's most ambitious founders and help them bring their breakthrough ideas to life.
